Tay-Sachs disease is inherited in the autosomal recessive pattern, depicted above.
Find information on thousands of medical conditions and prescription drugs.

Tay-Sachs disease

Tay-Sachs disease (abbreviated TSD, also known as "GM2 gangliosidosis") is a fatal genetic disorder, inherited in an autosomal recessive pattern, in which harmful quantities of a fatty substance called ganglioside GM2 accumulate in the nerve cells in the brain. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Candidiasis
Tachycardia
Taeniasis
Talipes equinovarus
TAR syndrome
Tardive dyskinesia
Tarsal tunnel syndrome
Tay syndrome ichthyosis
Tay-Sachs disease
Telangiectasia
Telangiectasia,...
TEN
Teratoma
Teratophobia
Testotoxicosis
Tetanus
Tetraploidy
Thalassemia
Thalassemia major
Thalassemia minor
Thalassophobia
Thanatophobia
Thoracic outlet syndrome
Thrombocytopenia
Thrombocytosis
Thrombotic...
Thymoma
Thyroid cancer
Tick paralysis
Tick-borne encephalitis
Tietz syndrome
Tinnitus
Todd's paralysis
Topophobia
Torticollis
Touraine-Solente-Golé...
Tourette syndrome
Toxic shock syndrome
Toxocariasis
Toxoplasmosis
Tracheoesophageal fistula
Trachoma
Transient...
Transient Global Amnesia
Transposition of great...
Transverse myelitis
Traumatophobia
Treacher Collins syndrome
Tremor hereditary essential
Trichinellosis
Trichinosis
Trichomoniasis
Trichotillomania
Tricuspid atresia
Trigeminal neuralgia
Trigger thumb
Trimethylaminuria
Triplo X Syndrome
Triploidy
Trisomy
Tropical sprue
Tropophobia
Trypanophobia
Tuberculosis
Tuberous Sclerosis
Tularemia
Tungiasis
Turcot syndrome
Turner's syndrome
Typhoid
Typhus
Tyrosinemia
U
V
W
X
Y
Z
Medicines

The disease is named after the British ophthalmologist Warren Tay who first described the red spot on the retina of the eye in 1881, and the American neurologist Bernard Sachs who described the cellular changes of Tay-Sachs and noted an increased prevalence in the Eastern European Jewish population of 1887.

Symptoms

Infants with Tay-Sachs disease appear to develop normally for the first six months of life. Then, as nerve cells become distended with fatty material, a relentless deterioration of mental and physical abilities occurs. The child becomes blind, deaf, and unable to swallow. Muscles begin to atrophy and paralysis sets in.

A much rarer form of the disorder which occurs in patients in their twenties and early thirties is characterized by unsteadiness of gait and progressive neurological deterioration. Patients with Tay-Sachs have a "cherry-red" spot in the back of their eyes (the retina).

Pathogenesis

The condition is caused by insufficient activity of an enzyme called hexosaminidase A that catalyzes the biodegradation of acidic fatty materials known as gangliosides. Gangliosides are made and biodegraded rapidly in early life as the brain develops. Patients and carriers of Tay-Sachs disease can be identified by a simple blood test that measures hexosaminidase A activity. Both parents must be carriers in order to have an affected child. Prenatal monitoring of pregnancies is available if desired.

To expand on the genetic basis, Tay-Sachs is an autosomal recessive genetic condition: if both parents are carriers, there is a 25% risk with each pregnancy for an affected child.

The disease results from mutations on chromosome 15 in the HEXA gene encoding the alpha-subunit of the lysosomal enzyme beta-N-acetylhexosaminidase A. This enzyme is necessary for breaking down N-galactosamine from GM2 gangliosides in brain and nerve cells. More than ninety mutations have been identified in the HEXA gene. These consist of base pair insertions, base pair deletions, splice site mutations, and point mutations. All of these mutations alter the protein product. For example, a four base pair insertion in exon 11 results in an altered reading frame for the HEXA gene while a three base pair deletion eliminates the amino acid phenylalanine from the protein product at position 304. A G to C point mutation at amino acid 180 changes the codon UAC to UAG causing termination of the polypeptide. A G to A point mutation at amino acid 170 changes the codon CGA to CAA and CGG to CAG which produces glutamine instead of arginine. A G to C mutation in the splice site of intron 12 has also been identified. This mutation creates a recognition site for the restriction enzyme Ddel resulting in abnormal splicing and the production of aberrant mRNA species.

Read more at Wikipedia.org


[List your site here Free!]


Tay-Sachs Disease
From Gale Encyclopedia of Childhood and Adolescence, 4/6/01

Tay-Sachs disease is a fatal childhood degenerative disease of the central nervous system that is genetically transmitted and found primarily among Jews of Eastern European ancestry (Ashkenazim). Tay-Sachs is caused by the absence of a particular enzyme, hexosaminidase (hex-A). Without hex-A, fatty substances (lipids) build up in the brain and interfere with the functioning of the central nervous system. The disease is named for two doctors who were pioneers in identifying and describing it. In 1881, Warren Tay, a British ophthalmologist, first noted the red spot on the retina that is a distinctive mark of the disorder. In the United States, neurologist Bernard Sachs identified the cause of the illness and discovered its prevalence among Ashkenazic Jews in 1887.

Although the disease is already present in utero, the symptoms do not usually become apparent until the child is about five or six months old, at which point development is arrested and starts to regress. The child stops crawling and becomes unable to sit, push himself up, or perform other simple motor activities. He becomes easily startled, exhibiting an abnormal jerking motion (myoclonus), begins to lose his vision, and develops respiratory problems. By the second year of the disease, there is severe deterioration, including blindness, paralysis, deafness, seizures, and dementia, followed by death, usually between the ages of three and five.

Tay-Sachs is transmitted by a recessive gene present in both parents, even though they do not have the disease themselves. For the disease to be passed on, both parents must be carriers. However, if even one parent is a carrier, the child has a 50% chance of also being a carrier. If both parents are carriers, their child has a 25% chance of being born with the disease. Although Tay-Sachs has been reported among other groups, including Amish and Italian Catholics, it is primarily found in Jews of Eastern European descent, in whom it is 100 times more frequent than in the general population. The average person has a one in 300 chance of being a carrier; an Ashkenazic Jew's chance of carrying the disease is about one in 30.

In the early 1970s, a pilot program was set up for genetic screening of potential Tay-Sachs carriers, who have visibly lower levels of the hex-A enzyme than non-carriers, although they have enough to prevent the lipid buildup that produces the disease. Testing centers were set up in Baltimore, Maryland, and an extensive educational campaign was launched in the Jewish community. More than 60,000 couples had their blood tested for levels of hex-A, and the screening identified a number of carriers of the disease. Since then, the International Tay-Sachs Disease Testing, Quality Control, and Data Collection Center has established and monitored testing centers throughout the world, and nearly one million young adults, both Jews and non-Jews, have been tested for the disease. The incidence of Tay-Sachs in the United States and Canada has plummeted from 60 new cases per year before 1970 to only three to five cases by the early 1990s--a 90% reduction. Couples who are carriers, and who decide to conceive, can learn in advance through amniocentesis whether their child will have the disease. More than 100 hospitals and clinics throughout the United States provide genetic screening for Tay-Sachs on an ongoing basis. Currently, approximately 62,000 persons worldwide are tested for the disease each year, 35,000 of them in the United States. Due to dramatic effectiveness of this testing program in reducing the incidence of the disease, it is considered a model for the application of genetic screening programs for other diseases.

One surprising discovery has been that the prevalence of Tay-Sachs disease among French-Canadian Catholics, which had received little attention until very recently, is roughly equal to that of Ashkenazic Jews. In a medical breakthrough of special significance for Catholic couples, who are unwilling to abort a pregnancy for religious reasons, a physician in Virginia has developed a procedure for screening an egg fertilized in a laboratory to determine if the child will be born with the disease. If it is found to be healthy, the pre-embryo can then be implanted in the mother's womb, and the parents can be assured of giving birth to a healthy baby.

At present there is no treatment for Tay-Sachs. Attempts to inject patients with the missing enzyme hex-A have failed because the substance was not absorbed by the brain after entering the bloodstream. Research on a cure is currently underway in the United States, Europe, and South Africa, with new hope provided by ongoing advances in molecular genetics and other relevant fields. The National Tay-Sachs and Allied Diseases Association (NTSAD), founded in 1958, promotes research, testing, and public education about the disease.

Further Reading

For Your Information

Books

  • Brown, Fern G. Hereditary Diseases. New York: Franklin Watts, 1987.

Gale Encyclopedia of Childhood & Adolescence. Gale Research, 1998.

Return to Tay-Sachs disease
Home Contact Resources Exchange Links ebay